Pharmacologic management of Alzheimer disease part II: Antioxidants, antihypertensives, and ergoloid derivatives

被引:29
作者
Flynn, BL
Ranno, AE
机构
[1] Creighton Univ, Sch Pharm & Allied Hlth Profess, Dept Pharmaceut & Adm Sci, Omaha, NE 68178 USA
[2] St Joseph Villa Nursing Ctr, Omaha, NE USA
[3] Univ Nebraska, Med Ctr, Coll Med, Omaha, NE USA
关键词
antioxidants; antihypertensives; ergoloid derivatives; Alzheimer disease;
D O I
10.1345/aph.17172
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To provide information about research evaluating antioxidants in Alzheimer disease (AD) and to discuss the potential role of beta-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD therapy. DATA SOURCES: Studies, review articles, and editorials identified from MEDLINE searches (from 1989 to 1997) and bibliographies of identified cuticles. STUDY SELECTION: Studies and review articles addressing antioxidant, antihypertensive, and ergoloid derivative pharmacotherapy research. DATA EXTRACTION: Pertinent information was selected and the data synthesized into a review format. DATA SYNTHESIS: AD is a progressive neuropsychiatric disorder of unknown etiology. Studies evaluating the possible association between a free radical mechanism in PLD and the potential role of antioxidants are reviewed. Additionally, the role of beta-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD management are discussed. CONCLUSIONS: Preliminary evidence suggests that antioxidants may have a protective effect against the development of AD. Additional prospective, double-blind. placebo-controlled studies are needed to determine the role of antioxidants in the prevention and management of AD. Understanding the role of antioxidants in AD may suggest alternative agents that have similar pharmacologic activity. beta-Blockers may be an option to control agitation in PLD patients for whom anxiolytics or antipsychotics are ineffective or are contraindicated because of their adverse effect profiles. Other agents that may have a role in AD therapy include angiotensin-converting enzyme inhibitors, nimodipine, and ergoloid derivatives. Clonidine and guanfacine have thus far shown little promise in improving cognitive function in AD. Further prospective, double-blind, placebo-controlled trials will be necessary to elucidate the rule of these agents in PLD management.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 86 条
[61]  
Reynolds Gavin P., 1993, Biochemical Society Transactions, V21, p221S
[62]   ON THE POSSIBLE ROLE OF IRON-INDUCED FREE-RADICAL PEROXIDATION IN NEURAL DEGENERATION IN ALZHEIMERS-DISEASE [J].
RICHARDSON, JS ;
SUBBARAO, KV ;
ANG, LC .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 648 :326-327
[63]  
ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356
[64]  
RZIGKEIT H, 1986, SYNDROM KURTEST ERFA
[65]   INTRAVENOUS BENZTROPINE AND PROPRANOLOL CHALLENGES IN TARDIVE AKATHISIA [J].
SACHDEV, P ;
LONERAGAN, C .
PSYCHOPHARMACOLOGY, 1993, 113 (01) :119-122
[66]   Antioxidant treatment with phenyl-alpha-tert-butyl nitrone (PBN) improves the cognitive performance and survival of aging rats [J].
Sack, CA ;
Socci, DJ ;
Crandall, BM ;
Arendash, GW .
NEUROSCIENCE LETTERS, 1996, 205 (03) :181-184
[67]   NICERGOLINE IN SENILE DEMENTIA OF ALZHEIMER-TYPE AND MULTI INFARCT DEMENTIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL AND EEG/ERP MAPPING STUDY [J].
SALETU, B ;
PAULUS, E ;
LINZMAYER, L ;
ANDERER, P ;
SEMLITSCH, HV ;
GRUNBERGER, J ;
WICKE, L ;
NEUHOLD, A ;
PODREKA, I .
PSYCHOPHARMACOLOGY, 1995, 117 (04) :385-395
[68]   ELEMENTAL IMBALANCES IN THE OLFACTORY PATHWAY IN ALZHEIMERS-DISEASE [J].
SAMUDRALWAR, DL ;
DIPRETE, CC ;
NI, BF ;
EHMANN, WD ;
MARKESBERY, WR .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1995, 130 (02) :139-145
[69]   A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease [J].
Sano, M ;
Ernesto, C ;
Thomas, RG ;
Klauber, MR ;
Schafer, K ;
Grundman, M ;
Woodbury, P ;
Growdon, J ;
Cotman, DW ;
Pfeiffer, E ;
Schneider, LS ;
Thal, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) :1216-1222
[70]   GUANFACINE TREATMENT OF ALZHEIMERS-DISEASE [J].
SCHLEGEL, J ;
MOHR, E ;
WILLIAMS, J ;
MANN, U ;
GEARING, M ;
CHASE, TN .
CLINICAL NEUROPHARMACOLOGY, 1989, 12 (02) :124-128